Furthermore, sorafenib maintenance therapy reduced the risk of relapse and death after allogeneic stem cell transplantation in FLT3-ITD-positive AML in the SORMAIN trial [27]. The gene discussed is FLT3; the disease is acute myeloid leukemia.